Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Anaptysbio (ANAB) Retained Earnings (2017 - 2025)

Anaptysbio filings provide 10 years of Retained Earnings readings, the most recent being -$24000.0 for Q4 2025.

  • For the quarter ending Q4 2025, Retained Earnings fell 107.87% year-over-year to -$24000.0, compared with a TTM value of -$24000.0 through Dec 2025, down 107.87%, and an annual FY2025 reading of -$24000.0, down 107.87% over the prior year.
  • Retained Earnings hit -$24000.0 in Q4 2025 for Anaptysbio, up from -$822.2 million in the prior quarter.
  • The five-year high for Retained Earnings was $759000.0 in Q3 2024, with the low at -$837.3 million in Q2 2025.
  • Median Retained Earnings over the past 5 years was -$2.9 million (2022), compared with a mean of -$229.0 million.
  • The sharpest move saw Retained Earnings crashed 221810.23% in 2022, then soared 138.27% in 2024.
  • Year by year, Retained Earnings stood at -$422000.0 in 2021, then crashed by 1143.13% to -$5.2 million in 2022, then surged by 84.81% to -$797000.0 in 2023, then soared by 138.27% to $305000.0 in 2024, then crashed by 107.87% to -$24000.0 in 2025.
  • According to Business Quant data, Retained Earnings over the past three periods came in at -$24000.0, -$822.2 million, and -$837.3 million for Q4 2025, Q3 2025, and Q2 2025 respectively.